Brief Introduction
This study aims to evaluate the safety and preliminary efficacy of a drug called Avelumab in combination with chemotherapya cancer treatment that uses drugs to kill or slow the growth of cancer cells, while minimising damage to healthy cells plus radiotherapy (CRT) in patients with resectable oesophageal/ gastro-oesophageal junctionthe area where the oesophagus and the stomach meet (GOJ) adenocarcinomacancer arising from mucus-producing glands in organs.
Intervention/Treatment
- Drug: Carboplatin
- Drug: Paclitaxel
- Intervention: Radiation therapya treatment that uses controlled doses of radiation to damage or kill cancer cells
- Drug: Avelumab
Inclusion Criteria
- Male/female patients aged 18 years or older.
- Histologically confirmed gastro-oesophageal junction or oesophageal adenocarcinoma. Oesophageal and gastroesophageal junction tumours should be TNM7 stage T1-3 and N0-N1, with no evidence of distant metastases (M0) where the MDT believes that an R0 resectionsurgical removal of tissue or part/all of an organ can be achieved at the outset. T4 or N2 cancers are excluded as per the CROSS trial eligibility and due to the possible variable need to prolong pre-operative chemotherapy or alternate chemotherapy regimen in CRT to reduce margin involvement and improve resectability.
- Absence of distant metastases on CT scan and PET scan and stagingthe process of determining how big the cancer is, where it started and if it has spread to other areas laparoscopya minimally invasive surgical procedure that uses small incisions to access the body for procedures, also known as keyhole surgery (where indicated) prior to study entry.
- No prior therapy for oesophageal or GOJ adenocarcinoma.